Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanROC EpiDOSE Trial: Low vs Standard Dose Epinephrine in Out-of-Hospital Cardiac Arrest
NCT03826524Phase 4Recruiting
- Sponsor
- Unity Health Toronto
- Start
- May 2023
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of epinephrine in cardiac arrest (SCA) (2 arms), sponsored by Unity Health Toronto. Primary endpoint: Survival to hospital discharge up to 5 years. Started May 2023; status: recruiting.
02
Drugs
epinephrine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT03826524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826524.